Details of Drug Interaction

Details of Drug-Drug Interaction

 Drug General Information (ID: DDIFX3K62J)
  Drug Name Pentoxifylline Drug Info Cyclandelate Drug Info
  Drug Type Small molecule Small molecule
  Therapeutic Class Vasodilator Agents Vasodilator Agents
  Structure

 Mechanism of Pentoxifylline-Cyclandelate Interaction (Severity Level: Moderate)
     Additive hypotensive effects Click to Show/Hide Mechanism Graph
Could Not Find 2D Structure
      Drug Name Pentoxifylline Cyclandelate
      Mechanism 1 Antihypertensive agent Antihypertensive agent
Voltage-gated calcium channel  Blocker
      Key Mechanism Factor 1
Factor Name Voltage-dependent L-type calcium channel Structure Sequence
Protein Family Calcium channel beta subunit family
Protein Function
Regulatory subunit of L-type calcium channels (PubMed:1309651, PubMed:8107964, PubMed:15615847). Regulates the activity of L-type calcium channels that contain CACNA1A as pore-forming subunit (By similarity). Regulates the activity of L-type calcium channels that contain CACNA1C as pore-forming subunit and increases the presence of the channel complex at the cell membrane (PubMed:15615847). Required for functional expression L-type calcium channels that contain CACNA1D as pore-forming subunit (PubMed:1309651). Regulates the activity of L-type calcium channels that contain CACNA1B as pore-forming subunit (PubMed:8107964).
    Click to Show/Hide
      Mechanism Description
  • Additive hypotensive effects by the combination of Pentoxifylline and Cyclandelate 
      Mechanism 2 Hypotensive effects Antihypertensive agent
Voltage-gated calcium channel  Blocker
      Key Mechanism Factor 2
Factor Name Voltage-dependent L-type calcium channel Structure Sequence
Protein Family Calcium channel beta subunit family
Protein Function
Regulatory subunit of L-type calcium channels (PubMed:1309651, PubMed:8107964, PubMed:15615847). Regulates the activity of L-type calcium channels that contain CACNA1A as pore-forming subunit (By similarity). Regulates the activity of L-type calcium channels that contain CACNA1C as pore-forming subunit and increases the presence of the channel complex at the cell membrane (PubMed:15615847). Required for functional expression L-type calcium channels that contain CACNA1D as pore-forming subunit (PubMed:1309651). Regulates the activity of L-type calcium channels that contain CACNA1B as pore-forming subunit (PubMed:8107964).
    Click to Show/Hide
      Mechanism Description
  • Additive hypotensive effects by the combination of Pentoxifylline and Cyclandelate 

Recommended Action
      Management Caution is advised if pentoxifylline is used in combination with hypotensive agents. Periodic systemic blood pressure monitoring is recommended.

References
1 Product Information. Trental (pentoxifylline). Hoechst Marion-Roussel Inc, Kansas City, MO.